tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Heart Failure D006333 36 associated lipids
Angioedema D000799 6 associated lipids
Fractures, Spontaneous D005598 4 associated lipids
Hydronephrosis D006869 4 associated lipids
Trypanosomiasis D014352 5 associated lipids
Alopecia D000505 14 associated lipids
Liver Diseases D008107 31 associated lipids
Corneal Diseases D003316 13 associated lipids
Testicular Diseases D013733 15 associated lipids
Facial Dermatoses D005148 7 associated lipids
Hypersensitivity D006967 22 associated lipids
Osteosarcoma D012516 50 associated lipids
Acne Vulgaris D000152 35 associated lipids
Urination Disorders D014555 9 associated lipids
Arterial Occlusive Diseases D001157 12 associated lipids
Anemia, Hemolytic D000743 4 associated lipids
Leukemia, Erythroblastic, Acute D004915 41 associated lipids
Vision Disorders D014786 10 associated lipids
Multiple Myeloma D009101 13 associated lipids
Osteochondrodysplasias D010009 3 associated lipids
Melanoma D008545 69 associated lipids
Hematologic Diseases D006402 3 associated lipids
Muscular Dystrophies D009136 10 associated lipids
Osteoporosis D010024 12 associated lipids
Anemia, Aplastic D000741 6 associated lipids
Kidney Diseases D007674 29 associated lipids
Hematuria D006417 13 associated lipids
Weight Gain D015430 101 associated lipids
Brain Diseases D001927 27 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Infection D007239 6 associated lipids
Abnormalities, Multiple D000015 13 associated lipids
Hypersensitivity, Delayed D006968 43 associated lipids
Glioma D005910 112 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Bone Diseases D001847 4 associated lipids
Leukemia P388 D007941 43 associated lipids
Ulcer D014456 16 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Obesity D009765 29 associated lipids
Thrombosis D013927 49 associated lipids
Bradycardia D001919 13 associated lipids
Hemorrhage D006470 15 associated lipids
Proteinuria D011507 30 associated lipids
Lymphoma D008223 18 associated lipids
Femur Head Necrosis D005271 5 associated lipids
Alzheimer Disease D000544 76 associated lipids
Drug Hypersensitivity D004342 20 associated lipids
Eye Diseases D005128 12 associated lipids
Arteriosclerosis D001161 86 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Alessiani M et al. Adverse effects of FK 506 overdosage after liver transplantation. 1993 Transplant. Proc. pmid:7679825
Klintmalm GB et al. Use of FK 506 for the prevention of recurrent allograft rejection after successful conversion from cyclosporine for refractory rejection. US Multicenter FK 506 Liver Study Group. 1993 Transplant. Proc. pmid:7679826
Jordan ML et al. FK 506 salvage of renal allografts with ongoing rejection failing cyclosporine immunosuppression. 1993 Transplant. Proc. pmid:7679827
Klintmalm GB et al. Prognostic factors for successful conversion from cyclosporine to FK 506-based immunosuppressive therapy for refractory rejection after liver transplantation. US Multicenter FK 506 Liver Study Group. 1993 Transplant. Proc. pmid:7679828
Schweizer M et al. Sensitivity of mitochondrial peptidyl-prolyl cis-trans isomerase, pyridine nucleotide hydrolysis and Ca2+ release to cyclosporine A and related compounds. 1993 Biochem. Pharmacol. pmid:7680201
Hirao A et al. Effects of immunosuppressants, FK506, deoxyspergualin, and cyclosporine A on immature human hematopoiesis. 1993 Blood pmid:7680241
Tamura K et al. Suppression of autoimmune thyroid disease by FK 506: influence on thyroid-infiltrating cells, adhesion molecule expression and anti-thyroglobulin antibody production. 1993 Clin. Exp. Immunol. pmid:7680293
Armitage JM et al. A decade (1982 to 1992) of pediatric cardiac transplantation and the impact of FK 506 immunosuppression. 1993 J. Thorac. Cardiovasc. Surg. pmid:7680396
Thomson AW et al. ICAM-1 and E-selectin expression in lesional biopsies of psoriasis patients responding to systemic FK 506 therapy. 1993 Autoimmunity pmid:7505632
López-Gil JA and García Sáiz M [FK506: an immunosuppressor for the '90's?]. 1993 Med Clin (Barc) pmid:7505871
Kagayama A et al. Oral absorption of FK506 in rats. 1993 Pharm. Res. pmid:7505939
Rao PN et al. Prediction of early graft function by effluent levels of hyaluronic acid in clinical liver transplantation. 1993 Transplant. Proc. pmid:7682366
Hutchison KA et al. FK506 binding to the 56-kilodalton immunophilin (Hsp56) in the glucocorticoid receptor heterocomplex has no effect on receptor folding or function. 1993 Biochemistry pmid:7682438
Shorrock C and Neuberger J The changing face of liver transplantation. 1993 Gut pmid:7682532
Iwasaki K et al. Effects of twenty-three drugs on the metabolism of FK506 by human liver microsomes. 1993 Res. Commun. Chem. Pathol. Pharmacol. pmid:7508138
Schwaninger M et al. Inhibition of cAMP-responsive element-mediated gene transcription by cyclosporin A and FK506 after membrane depolarization. 1993 J. Biol. Chem. pmid:7693684
Smith DF et al. FKBP54, a novel FK506-binding protein in avian progesterone receptor complexes and HeLa extracts. 1993 J. Biol. Chem. pmid:7693698
Thomson AW et al. Comparative effects of rapamycin, FK 506 and cyclosporine on antibody production, lymphocyte populations and immunoglobulin isotype switching in the rat. 1993 Immunopharmacol Immunotoxicol pmid:7693791
Tzakis AG et al. Intestinal transplantation in children under FK 506 immunosuppression. 1993 J. Pediatr. Surg. pmid:7693907
McMichael J et al. Computer-guided concentration-controlled trials in autoimmune disorders. 1993 Ther Drug Monit pmid:7510078
Lemster B et al. Blood lymphocytes of autoimmune disease patients receiving FK506 exhibit normal ex vivo cytokine gene expression and proliferative responses. 1993 Immunol. Lett. pmid:7510265
Parent SA et al. Calcineurin-dependent growth of an FK506- and CsA-hypersensitive mutant of Saccharomyces cerevisiae. 1993 J. Gen. Microbiol. pmid:7510323
Ocain TD et al. A nonimmunosuppressive triene-modified rapamycin analog is a potent inhibitor of peptidyl prolyl cis-trans isomerase. 1993 Biochem. Biophys. Res. Commun. pmid:7685167
Asami M et al. Detection of the FK506-FKBP-calcineurin complex by a simple binding assay. 1993 Biochem. Biophys. Res. Commun. pmid:7685169
Metcalfe S et al. Prodigiosin 25C: effect in in vitro models for T cell activation and T cell cycling and in vivo for rat heart allografts. 1993 Int. Arch. Allergy Immunol. pmid:7685216
Bumgardner GL and Roberts JP New immunosuppressive agents. 1993 Gastroenterol. Clin. North Am. pmid:7685324
Henke W and Jung K Comparison of the effects of the immunosuppressive agents FK 506 and cyclosporin A on rat kidney mitochondria. 1993 Biochem. Pharmacol. pmid:7690566
Antoni FA et al. Inhibitory role for calcineurin in stimulus-secretion coupling revealed by FK506 and cyclosporin A in pituitary corticotrope tumor cells. 1993 Biochem. Biophys. Res. Commun. pmid:7687429
Denesyuk AI et al. Comparison of conformations of cyclosporin A and macrolide FK506 fragments: localization of putative binding sites with phosphatase calcineurin. 1993 Biochem. Biophys. Res. Commun. pmid:7687433
Altmeyer A and Dumont FJ Rapamycin inhibits IL-1-mediated interferon-gamma production in the YAC-1 T cell lymphoma. 1993 Cytokine pmid:7687472
Przepiorka D et al. Bronchiolitis obliterans organizing pneumonia in a BMT patient receiving FK506. 1993 Bone Marrow Transplant. pmid:7687503
Ueda D et al. Influence of FK 506 on renal blood flow. 1993 Transplant. Proc. pmid:7689280
Ohzato H et al. Serum interleukin-6 levels as an indicator of acute rejection after liver transplantation in cynomologous monkeys. 1993 Surg. Today pmid:7689373
Fesik SW NMR structure-based drug design. 1993 J. Biomol. NMR pmid:7689377
McManus BM et al. Direct myocardial injury by enterovirus: a central role in the evolution of murine myocarditis. 1993 Clin. Immunol. Immunopathol. pmid:7689428
Hirai T et al. Prolonged lung allograft survival with a short course of FK 506. 1993 J. Thorac. Cardiovasc. Surg. pmid:7678313
Ibarra F et al. Bidirectional regulation of Na+,K(+)-ATPase activity by dopamine and an alpha-adrenergic agonist. 1993 Proc. Natl. Acad. Sci. U.S.A. pmid:7678337
Murase N et al. Graft-versus-host disease after brown Norway-to-Lewis and Lewis-to-Brown Norway rat intestinal transplantation under FK506. 1993 Transplantation pmid:7678353
Sattler M et al. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. 1992 Sep-Oct Drug Metab. Dispos. pmid:1385058
Bowman H and Lennard TW Immunosuppressive drugs. 1992 Nov 4-17 Br J Hosp Med pmid:1282440
Nazer H et al. FK 506 associated disorders in liver transplantation. 1992 May-Jun J. Gastroenterol. Hepatol. pmid:1377038
Arai S et al. The impact of FK506 on graft coronary disease of rat cardiac allograft--a comparison with cyclosporine. 1992 Jul-Aug J. Heart Lung Transplant. pmid:1379829
Fagiuoli S et al. FK 506: a new immunosuppressive agent for organ transplantation. Pharmacology, mechanism of action and clinical applications. 1992 Jul-Aug Ital J Gastroenterol pmid:1381245
Tong J et al. Effect of FK-506 and cyclosporin A on in vitro CFU-GM growth in severe aplastic anemia patients. 1992 Jul-Aug Haematologica pmid:1385279
Mizuno K et al. Modulation of multidrug resistance by immunosuppressive agents: cyclosporin analogues, FK506 and mizoribine. 1992 Jan-Feb Anticancer Res. pmid:1373592
Takaya S et al. The adverse impact on liver transplantation of using positive cytotoxic crossmatch donors. 1992 Transplantation pmid:1371195
Ricordi C et al. Effect of FK 506 on human pancreatic islets following renal subcapsular transplantation in diabetic nude mice. 1992 Transplant. Proc. pmid:1376512
Foor F et al. Calcineurin mediates inhibition by FK506 and cyclosporin of recovery from alpha-factor arrest in yeast. 1992 Nature pmid:1281518
Price DJ et al. Rapamycin-induced inhibition of the 70-kilodalton S6 protein kinase. 1992 Science pmid:1380182
Langrehr JM et al. Evidence that indefinite survival of small bowel allografts achieved by a brief course of cyclosporine or FK506 is not due to systemic hyporesponsiveness. 1992 Transplantation pmid:1384185